SkinBioTherapeutics PLC
LSE:SBTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.25
26.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
SkinBioTherapeutics PLC
Total Current Liabilities
SkinBioTherapeutics PLC
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SkinBioTherapeutics PLC
LSE:SBTX
|
Total Current Liabilities
ÂŁ1.4m
|
CAGR 3-Years
60%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Current Liabilities
$58m
|
CAGR 3-Years
33%
|
CAGR 5-Years
98%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Current Liabilities
$69.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Current Liabilities
ÂŁ212m
|
CAGR 3-Years
51%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Current Liabilities
ÂŁ131.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Current Liabilities
ÂŁ69.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
23%
|
|
SkinBioTherapeutics PLC
Glance View
SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Macclesfield, Cheshire and currently employs 7 full-time employees. The company went IPO on 2017-04-05. The firm is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis, medical device applications and others. The Company’s platform technology, SkinBiotix, is designed to promote skin health by harnessing the beneficial properties of probiotic bacteria and the active components derived from them. SkinBiotix protects the skin from infection and increases the rate of skin healing in response to injury. The firm's AxisBiotix technology is based on the emerging area of science that is focused on the gut-skin axis and the constitution of the gut microbiome plays a role in various diseases, such as psoriasis. AxisBiotix-Ps is the product developed by the Company that uses the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
See Also
What is SkinBioTherapeutics PLC's Total Current Liabilities?
Total Current Liabilities
1.4m
GBP
Based on the financial report for Dec 31, 2024, SkinBioTherapeutics PLC's Total Current Liabilities amounts to 1.4m GBP.
What is SkinBioTherapeutics PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
51%
Over the last year, the Total Current Liabilities growth was 186%. The average annual Total Current Liabilities growth rates for SkinBioTherapeutics PLC have been 60% over the past three years , 51% over the past five years .